This finding is further supported by a clinical trial reported by Matthews et al. [40], in which 24 weeks of treatment with MAO-B inhibitor, rasagiline, in patients with AD did not result in changes of flortaucipir binding in cortical regions. This evidence concerns the gene MAOB and Alzheimer disease.